With a market capitalization (market cap) of $4.76B — a measure of how much the company is worth — Haemonetics Corporation is the 1463rd most valuable company in Healthcare as of August 18, 2026. Shares trade at $104.65, up +15.93% on the day.
of 2,587
price ÷ annual EPS
FY 2026
FY 2026
FY 2026
FY 2026
FY 2026
FY 2026
FY 2026
FY 2026
FY 2026
FY 2026
FY 2026
FY 2026
FY 2026
FY 2026
FY 2026
FY 2026
FY 2026
Haemonetics Corporation is a healthcare enterprise dedicated to providing medical products and comprehensive solutions, structured into three main business areas: Plasma, Blood Center, and Hospital. In its Plasma segment, the company develops automated plasma collection systems, exemplified by the NexSys PCS and PCS2 devices, along with necessary disposables and intravenous solutions. It also offers integrated information technology platforms and the NexLynk DMS donor management system to help plasma customers efficiently manage their donors, operations, and supply chains. The Blood Center division provides advanced automated blood component and manual whole blood collection technologies. This includes MCS brand apheresis equipment for selectively collecting blood components, as well as disposable kits for whole blood collection and storage. Its software offerings feature the SafeTrace Tx blood bank information system and BloodTrack, a sophisticated suite of blood management software and hardware designed to enhance hospital blood bank functionalities and facilitate bedside transfusions. For the Hospital sector, Haemonetics offers hemostasis analyzer systems like TEG, ClotPro, and HAS, which deliver crucial assessments of a patient's overall clotting ability. The TEG Manager software links these analyzers throughout a facility, enabling clinicians to remotely access active and past test results to inform treatment decisions. Additionally, the Cell Saver Elite+ system supports autologous blood recovery across a wide range of surgical procedures, including cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological operations. The company distributes its products and solutions through its own direct sales teams, independent distributors, and sales representatives. Haemonetics Corporation was established in 1971 and is based in Boston, Massachusetts.
Visit websiteAs of August 18, 2026, Haemonetics Corporation (HAE) is worth $4.76B — this is its market capitalization, the total value of all its outstanding shares.
Haemonetics Corporation’s market cap is $4.76B, which ranks it #1463 among the most valuable companies in the Healthcare sector tracked on MarketCapLens.
Haemonetics Corporation (HAE) shares trade at $104.65, up 15.93% on the day, as of August 18, 2026.
Fundamentals are annual. Figures labeled with their fiscal year.
FY 2026
Haemonetics Corporation trades at a price-to-earnings (P/E) ratio of 51.0, based on its latest share price and annual earnings per share.